Richard Wu

2.7k total citations · 2 hit papers
19 papers, 1.7k citations indexed

About

Richard Wu is a scholar working on Surgery, Molecular Biology and Dermatology. According to data from OpenAlex, Richard Wu has authored 19 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 3 papers in Molecular Biology and 3 papers in Dermatology. Recurrent topics in Richard Wu's work include Lipoproteins and Cardiovascular Health (6 papers), Dermatology and Skin Diseases (3 papers) and Asthma and respiratory diseases (3 papers). Richard Wu is often cited by papers focused on Lipoproteins and Cardiovascular Health (6 papers), Dermatology and Skin Diseases (3 papers) and Asthma and respiratory diseases (3 papers). Richard Wu collaborates with scholars based in United States, Germany and France. Richard Wu's co-authors include Evan A. Stein, Robert Dufour, Robert Weiss, Jean Bergeron, Daniel Gaudet, Robert Pordy, Neil M.H. Graham, Marius Ardeleanu, Gianluca Pirozzi and Eric L. Simpson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Richard Wu

19 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

2012 505 citations Evan A. Stein, Scott Mellis et al. New England Journal of Medicine profile →
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

2012 463 citations Evan A. Stein, Jean Bergeron et al. The Lancet profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Richard Wu	918	353	303	289	236	19	1.7k
Cassandra E. Milmont	210 0.2×	203 0.6×	58 0.2×	21 0.1×	330 1.4×	13	1.8k
Cara East	921 1.0×	111 0.3×	85 0.3×	12 0.0×	86 0.4×	50	1.6k
David W. Donley	511 0.6×	208 0.6×	13 0.0×	156 0.5×	61 0.3×	15	2.6k
Li Yin	434 0.5×	129 0.4×	58 0.2×	15 0.1×	373 1.6×	42	1.4k
Steven G. Smith	659 0.7×	269 0.8×	8 0.0×	571 2.0×	907 3.8×	78	2.5k
Laura Kruper	323 0.4×	66 0.2×	68 0.2×	21 0.1×	289 1.2×	66	1.7k
Alessandro Giunta	151 0.2×	422 1.2×	105 0.3×	26 0.1×	770 3.3×	78	1.3k
Michelle Orme	52 0.1×	34 0.1×	103 0.3×	65 0.2×	81 0.3×	38	949
Dorothy McCabe	122 0.1×	24 0.1×	183 0.6×	57 0.2×	896 3.8×	37	2.5k
Ruvie Martin	138 0.2×	129 0.4×	19 0.1×	49 0.2×	1.0k 4.3×	29	2.1k

Countries citing papers authored by Richard Wu

Since Specialization

Citations

This map shows the geographic impact of Richard Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Wu more than expected).

Fields of papers citing papers by Richard Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Wu. The network helps show where Richard Wu may publish in the future.

Co-authorship network of co-authors of Richard Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Wu. A scholar is included among the top collaborators of Richard Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Wu. Richard Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Baddour, Khalil, Richard Wu, Teresa Hagan Thomas, et al.. (2023). Longitudinal Analysis of Caregiver Burden in Head and Neck Cancer. JAMA Otolaryngology–Head & Neck Surgery. 149(8). 681–681. 9 indexed citations

Emery, Paul, Juan Rondon, Janie Parrino, et al.. (2018). Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Lara D. Veeken. 58(5). 849–858. 83 indexed citations

Simpson, Eric L., Abhijit Gadkari, Margitta Worm, et al.. (2016). Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). Journal of the American Academy of Dermatology. 75(3). 506–515. 131 indexed citations

Simpson, Eric L., Thomas Bieber, Laurent Eckert, et al.. (2016). Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. Journal of the American Academy of Dermatology. 74(3). 491–498. 229 indexed citations

Koren, Michael J., Eli M. Roth, James M. McKenney, et al.. (2015). Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgraduate Medicine. 127(2). 125–132. 15 indexed citations

Simpson, Eric L., Margitta Worm, Weily Soong, et al.. (2015). Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology. 135(2). AB167–AB167. 8 indexed citations

Sundy, John S., H. Ralph Schumacher, Alan Kivitz, et al.. (2014). Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study. The Journal of Rheumatology. 41(8). 1703–1711. 50 indexed citations

Ren, Haobo, Weining Shen, Richard Wu, & Yuhwen Soo. (2013). Moment estimation based on quantiles. Wiley Interdisciplinary Reviews Computational Statistics. 5(5). 387–390. 2 indexed citations

Lovell, Daniel J., Edward H. Giannini, Andreas Reiff, et al.. (2013). Long‐Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatism. 65(9). 2486–2496. 90 indexed citations

10.

Koren, Michael J., Evan A. Stein, Eli M. Roth, et al.. (2013). Efficacy, Safety and Tolerability of Alirocumab 150 mg Q2W, a Fully Human PCSK9 Monoclonal Antibody: A Pooled Analysis of 352 Patients from Phase 2. Journal of clinical lipidology. 7(3). 279–280. 4 indexed citations

11.

Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. Obstetrical & Gynecological Survey. 67(7). 413–414. 10 indexed citations

12.

Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. New England Journal of Medicine. 366(12). 1108–1118. 505 indexed citations breakdown →

13.

Stein, Evan A., Jean Bergeron, Daniel Gaudet, et al.. (2012). Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. The Lancet. 380(9836). 29–36. 463 indexed citations breakdown →

14.

Swergold, Gary D., W. Smith, Scott Mellis, et al.. (2011). Abstract 16265: Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 With a Monoclonal Antibody REGN727/SAR236553, Effectively Reduces Low-Density-Lipoprotein Cholesterol, as Mono or Add-on Therapy in Heterozygous Familial and Non Familial Hypercholesterolemia. Circulation. 124. 6 indexed citations

15.

Swergold, Gary D., et al.. (2011). REGN727/SAR236553, A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN ADMINISTERED SUBCUTANEOUSLY. Journal of the American College of Cardiology. 57(14). E2023–E2023. 3 indexed citations

16.

Daniels, James, et al.. (2011). Preventing Shoulder Pain after Cardiac Rhythm Management Device Implantation: A Randomized, Controlled Study. Pacing and Clinical Electrophysiology. 34(6). 672–678. 16 indexed citations

17.

Swergold, Gary D., et al.. (2011). REGN727/SAR236553, a Fully-Human Monoclonal Antibody to Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Decreases ApoB and Non-HDL-C When Administered Intravenously to Healthy Volunteers. Journal of clinical lipidology. 5(3). 219–219. 1 indexed citations

18.

Swergold, Gary D., et al.. (2010). Abstract 23251: Safety, Lipid, and Lipoprotein Effects of REGN727/SAR236553, a Fully-Human Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Monoclonal Antibody Administered Intravenously to Healthy Volunteers. Circulation. 122. 5 indexed citations

19.

DiMartino-Nardi, Joan, et al.. (1991). The Effect of Long-Acting Analog of Luteinizing Hormone-Releasing Hormone on Growth Hormone Secretory Dynamics in Children with Precocious Puberty*. The Journal of Clinical Endocrinology & Metabolism. 73(4). 902–906. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact